Sarepta Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Awesome. Hi, everyone. This is Maneka Mirchandaney from the Evercore ISI biotech team. Very pleased to be here with Sarepta. I have some important updates coming up early next year and beyond. So from the team we've got Doug Ingram, who's President and CEO; and Ian Estepan as well, who is the CFO. Thanks for joining us, Doug. I want to turn it over to you just to give us a quick snapshot of where Sarepta is right now.
Sure. And I'll be brief given the short amount of time we have. Look, we are exiting 2021 into 2022 with the wind at our backs. Things have gone from an execution perspective this year, very, very well. You'll remember back in February, we had our third approval, which is for AMONDYS. Revenue has done brilliantly. We had our 20th straight quarter of strong growth. We've had to raise our guidance over the course of this year twice. We'll now do between $605 million and $615 million this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
